Oxidative stress, Nrf2, and epigenetic modification contribute to anticancer drug resistance

被引：83

作者：

Kang K.A. ^{[1
]}

Hyun J.W. ^{[1
]}

机构：

[1] Department of Biochemistry, School of Medicine, Jeju National University, Jeju

来源：

Toxicological Research | 2017年 / 33卷 / 1期

基金：

新加坡国家研究基金会;

关键词：

Anticancer drug resistance; Epigenetic modification; Nrf2 transcription factor; Oxidative stress;

D O I：

10.5487/TR.2017.33.1.001

中图分类号：

学科分类号：

摘要：

Nuclear factor E2-related factor 2 (Nrf2), a transcription factor, controls the expression of genes encoding cytoprotective proteins, including antioxidant enzymes that combat oxidative and electrophilic stress to maintain redox homeostasis. However, recent studies demonstrated that, in cancer, aberrant activation of Nrf2 by epigenetic alterations promotes high expression of cytoprotective proteins, which can decrease the efficacy of anticancer drugs used for chemotherapy. In this review, we summarize recent findings regarding the relationship between oxidative stress, Nrf2, epigenetic modification, and anticancer drug resistance, which should aid in development of new strategies to improve chemotherapeutic efficacy.

引用

页码：1 / 5

页数：4

共 33 条

[1]

Bai X., Chen Y., Hou X., Huang M., Jin J., Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters, Drug Metab. Rev, 48, pp. 541-567, (2016)

[2]

Furfaro A.L., Piras S., Domenicotti C., Fenoglio D., De Luigi A., Salmona M., Moretta L., Marinari U.M., Pronzato M.A., Traverso N., Nitti M., Role of Nrf2, HO-1 and GSH in neuroblastoma cell resistance to bortezomib, PLoS ONE, 11, (2016)

[3]

Guo Y., Yu S., Zhang C., Kong A.N., Epigenetic regulation of Keap1-Nrf2 signaling, Free Radic. Biol. Med, 88, pp. 337-349, (2015)

[4]

Seton-Rogers S., Chemotherapy: preventing competitive release, Nat. Rev. Cancer, 16, (2016)

[5]

Holohan C., Van Schaeybroeck S., Longley D.B., Johnston P.G., Cancer drug resistance: an evolving paradigm, Nat. Rev. Cancer, 13, pp. 714-726, (2013)

[6]

Ramos P., Bentires-Alj M., Mechanism-based cancer therapy: resistanceto therapy, therapy for resistance, Oncogene, 34, pp. 3617-3626, (2015)

[7]

Gorrini C., Harris I.S., Mak T.W., Modulation of oxidative stress as an anticancer strategy, Nat. Rev. Drug Discov, 12, pp. 931-947, (2013)

[8]

Trachootham D., Alexandre J., Huang P., Targeting cancercells by ROS-mediated mechanisms: a radical therapeutic approach? Nat, Rev. Drug Discov, 8, pp. 579-591, (2009)

[9]

Liu Y., Li Q., Zhou L., Xie N., Nice E.C., Zhang H., Huang C., Lei Y., Cancer drug resistance: redox resetting renders a way, Oncotarget, 7, pp. 42740-42761, (2016)

[10]

Debatin K.M., Krammer P.H., Death receptors in chemotherapy and cancer, Oncogene, 23, pp. 2950-2966, (2004)

← 1 2 3 4 →